Efficacy of Danzhixiaoyao tablets combined with methylcobalamin tablets in the treatment of burning mouth syndrome: an open-label, randomized controlled trial

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

Registry name: Chinese Clinical trail Registry Registration number: ChiCTR2000038189 Date of Registration: 2020-09-13 Please visit ( https://www.chictr.org.cn/showproj.html?proj=61462 ) to the protocol.

Who Took Part

The abstract describes 78 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Collect a total of 78 patients (75 female patients and 3 male patients) from the oral mucosa department who were considered eligible fromOctober 2020 to October 2022.The patients were randomized and divided into trial group and control group.The trail group received danzhixiaoyao pills and mecobalamine tablets while the control group was given mecobalamine tablets.The Visual Analogue Scale (VAS), Beck Anxiety Inventory(BAI), Beck Depression Inventory (BDI), Oral Health Impact Profile (OHIP-14), Traditional Chinese medicine(TCM) syndrome integral and adverse reactions were performed at baseline and after 2, 4, and 6 weeks of treatment.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.

Descriptive statistics, including the Wilcoxon rank-sum test and the Chi-square test for median comparisons between different times, were used.

What Was Measured

PubMed files the paper under topics including Burning Mouth Syndrome, Vitamin B 12, Drugs, Chinese Herbal and Tablets.

Author keywords: Anxiety, Chinese patent medicine, Chinese traditional treatment, Danzhixiaoyao pills, Depression and Traditional Chinese medicine(TCM).

What This Means in Plain Language

The paper is a randomized study of Cyanocobalamin (Vitamin B12) in 78 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (BMC oral health), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.